ArticleMedicine2026
Association between the non-HDL-c to HDL-c ratio and mortality risk in cardiorenal syndrome: A population-based study from 1999 to 2018 NHANES.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is a novel biomarker that integrates atherogenic and atheroprotective lipoprotein profiles. We aimed to examine the prognostic significance of NHHR in patients with cardiorenal syndrome (CRS), a vulnerable population with significantly increased risk of mortality. We analyzed data from 1408 US adults with CRS, defined as the coexistence of cardiovascular disease (CVD) and chronic kidney disease, from the 1999 to 2018 National Health and Nutrition Examination Survey. The primary and secondary outcomes were all-cause and CVD mortality, respectively. The relationships between NHHR and mortality outcomes were analyzed using Cox proportional hazards regression analysis, restricted cubic spline modeling, and subgroup analyses. Over a median follow-up of 75 months, 802 deaths (53.63%) occurred, including 373 from CVD. We identified a significant nonlinear, L-shaped association between NHHR and both all-cause and CVD mortality, with inflection points at NHHR = 3.09 and 3.16, respectively. Piecewise regression analysis indicated that the multivariate-adjusted hazard ratios (95% confidence intervals) for all-cause and CVD mortality were 0.64 (0.53-0.76) and 0.60 (0.45-0.79), respectively, below the inflection points, and 0.83 (0.73-0.95) and 0.91 (0.78-1.05), respectively, above the inflection points. Results remained consistent across subgroups stratified by age, sex, body mass index, diabetes status, physical activity, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio. NHHR demonstrates an independent, L-shaped relationship with all-cause and CVD mortality in a nationally representative cohort of adults with CRS. This simple ratio may serve as a valuable prognostic biomarker to identify high-risk CRS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.